patent.fyi
Applications  /  US 2026/0355180
United States Patent Application Publication

US 2026/0355180 A1

Published
Nov 12, 2026
Filed
Dec 1, 2023
Earliest date on the face
Dec 1, 2022
Classification
A61K 31/496
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Pair with platinum chemotherapy

What ifWhat if a platinum DNA-crosslinking agent is paired with the immunotherapy?
Claim language“at least one spliceosome modulator”

An infused platinum compound forms DNA crosslinks that stall replication in dividing tumor cells. A checkpoint-blocking antibody reduces inhibitory signaling in tumor-reactive T cells.

1.1Limit tumor cell invasion

What ifWhat if the treatment aims to reduce tumor cell invasion while preserving viability and proliferation during measurement?
Claim language“reducing tumor cell proliferation or inducing tumor cell killing”

An inhibitor of extracellular matrix metalloproteinases reduces matrix degradation by tumor cells. A matrix-coated porous membrane measures invasion, and parallel cell counts and viability measurements verify that the reduction occurs at exposures that preserve growth and survival.

1.3Block the CTLA-4 checkpoint

What ifWhat if the immunotherapy blocks CTLA-4 on T cells?
Claim language“a PD-1 inhibitor or PD-L1 inhibitor”

A monoclonal antibody blocks CTLA-4 binding to CD80 and CD86 on antigen-presenting cells. This preserves access to those ligands for CD28 and supports costimulation during T-cell priming.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Combination testing in veterinary tumor culture

A veterinary oncology laboratory cultures canine melanoma organoids with lymphocytes isolated from the same tumor. Replicate wells receive vehicle, a spliceosome modulator, a species-reactive PD-1 blocking antibody, or both agents. Imaging measures viable tumor area and phosphorylated MLKL in tumor cells across the four conditions.

Specific version of a part

Measure combination tumor killing

Expose matched tumor organoid cultures containing tumor-reactive T cells to the modulator alone, the antibody alone, both agents, or vehicle. Quantify dead tumor cells by imaging a tumor-cell marker together with a membrane-impermeant dye and compare the combination with the modulator alone.

Block tumor cell PD-L1

Use a monoclonal antibody that binds the extracellular domain of PD-L1 and blocks its interaction with PD-1. This reduces inhibitory signaling when a PD-1-expressing T cell encounters a PD-L1-expressing tumor cell.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2020/0352937 A1
Published
Nov 12, 2020
Filed
Oct 30, 2018
Class
A61K 31/496
Document BUS 2021/0346420 A1
Published
Nov 11, 2021
Filed
Oct 10, 2019
Class
A61K 31/713
Claim 1
Document A
Document B
1.1administering to said subject effective amounts at least one spliceosome modulator and at least one immunotherapy, thereby reducing tumor cell proliferation or inducing tumor cell killing which exceeds that observed in tumor cells treated with the modulator alone
The present disclosure is based on the observation that the combination of certain spliceosome modulators (e.g., pladienolide compounds) and BCL2, BCL2/BCLxL, or BCLxL inhibitors shows improved (e.g., synergistic) anticancer effects.
A · US 2020/0352937 A1 · ¶ 4
Macroscopic view showed that neither polyIC nor PD-L1 Ab inhibited HCC development in this model, while no tumor nodule was even visible in the combination group.
B · US 2021/0346420 A1 · ¶ 123
1.2wherein said spliceosome modulator is selected from pladienolide B, H3B-8800, sudemycin D6, and indisulam
Without wishing to be bound by any particular theory, as described herein, pladienolide derivatives E7107 and H3B-8800 may induce potent splicing modulation of MCL1 gene, leading to reduced expression of the functional full-length protein.
A · US 2020/0352937 A1 · ¶ 45
1.3said immunotherapy is a PD-1 inhibitor or PD-L1 inhibitor.
In some embodiments, the antibody is an anti-PD-L1 antibody.
B · US 2021/0346420 A1 · ¶ 23

An empty cell means only that no passage was reproduced there.

Statements in these documents
Effective therapies to overcome resistance to BCL2, BCL2/BCLxL, and BCLxL inhibitors are needed.
A · US 2020/0352937 A1 · ¶ 2
The present disclosure is based on the observation that the combination of certain spliceosome modulators (e.g., pladienolide compounds) and BCL2, BCL2/BCLxL, or BCLxL inhibitors shows improved (e.g., synergistic) anticancer effects.
A · US 2020/0352937 A1 · ¶ 4
HCC is a chemotherapy-resistant tumor with limited treatment options, including, surgical resection, liver transplantation, and local ablation at the early stages.
B · US 2021/0346420 A1 · ¶ 3
Unexpectedly, a synthetic double stranded RNA (dsRNA), polyinosinic-polycytidylic acid (polyIC), was previously identified to have a potent liver tumor-inhibitory role.
B · US 2021/0346420 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355180 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355180/, SHA-256 ab6330d8e14c9656fc6c6e627d184b77194e5928686877d96295550e31086450
First published
Permanent addresshttps://patent.fyi/US20260355180/
Content fingerprint (SHA-256)ab6330d8e14c9656fc6c6e627d184b77194e5928686877d96295550e31086450
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi